Kairos Pharma, Ltd.
KAPA · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | -0.55 | -0.26 | 0.21 |
| FCF Yield | 0.00% | -6.60% | -4.81% | -8.64% |
| EV / EBITDA | -13.30 | -6.64 | -9.20 | -24.30 |
| Quality | ||||
| ROIC | -17.81% | -22.98% | -17.75% | -27.68% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.60 | 0.57 | 0.57 | 1.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 100.00% | -12.75% | 60.40% | 10.74% |
| Safety | ||||
| Net Debt / EBITDA | 4.11 | 2.20 | 2.96 | 1.58 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -10.87 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,521.00 | -1,811.25 | 0.00 |